Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A compelling checkpoint combination
February 2019
SHARING OPTIONS:

ROCHESTER, N.Y.—Preclinical data on Vaccinex Inc.'s anti-SEMA4D monoclonal antibody has been published in Cancer Immunology Research, the company announced recently. Vaccinex looked at the potential of anti-SEMA4D in combination with checkpoint inhibitors to reduce function and recruitment of myeloid-derived suppressor cells within a tumor, which plays a role in resisting immune checkpoint blockade. As noted in a press release, “The study examined combination therapy with SEMA4D blockade plus CTLA-4 or PD-1 blockade, and we believe demonstrated an enhanced rejection of tumors or delay in their growth, which resulted in prolonged survival using each treatment.” Dr. Maurice Zauderer, CEO of Vaccinex, commented that “This preclinical study helped inform the development of VX15 (pepinemab) and the initiation of several Phase 1 and 1b/2 combination trials with checkpoint inhibitors.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.